ReachMD
CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Besuch unbedingt die Website des Podcasts und unterstütze die Macher: reachmd.com
Wo hören?
Podcasts in der App Replaio Radio Bald verfügbarPodcasts kommen bald in die App. Installiere sie jetzt und erlebe als Erster einen ganz neuen Blick auf Podcasts
Kostenlos installieren
Android fast 10 Mio. Downloads · Bewertung 4,8
iOS bald
Folgen
FcRn: Same Class, Different Paths—Spot Agent Differentiators 24.03.2026 5:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
The 2-Point Signal: Apply ≥2-Point Rule 24.03.2026 5:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Shared Goals, Shared Gains: Align With Patient Preferences 24.03.2026 6:00
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Escalate With Intention: Stepwise, Target-Anchored Moves 24.03.2026 5:00
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
The IgG Clock: Redose Using IgG Kinetics 24.03.2026 4:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
When to Begin FcRn: Initiation Criteria, Key Evidence 24.03.2026 6:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Turning Flares Into Function: Flag Uncontrolled Disease 24.03.2026 4:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Minimal By Design: Define MSE Endpoints 24.03.2026 5:00
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Target Locked in gMG: Why T2T Matters 24.03.2026 6:15
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
FcRn: Same Class, Different Paths—Spot Agent Differentiators 24.03.2026 5:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
The 2-Point Signal: Apply ≥2-Point Rule 24.03.2026 5:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Shared Goals, Shared Gains: Align With Patient Preferences 24.03.2026 6:00
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Escalate With Intention: Stepwise, Target-Anchored Moves 24.03.2026 5:00
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
The IgG Clock: Redose Using IgG Kinetics 24.03.2026 4:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
When to Begin FcRn: Initiation Criteria, Key Evidence 24.03.2026 6:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Turning Flares Into Function: Flag Uncontrolled Disease 24.03.2026 4:30
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Minimal By Design: Define MSE Endpoints 24.03.2026 5:00
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
Target Locked in gMG: Why T2T Matters 24.03.2026 6:15
Faculty: Christyn Edmundson, MD Faculty: Gil I. Wolfe MD, FAAN This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and g...
DKA in Focus: What the New Consensus Means for Practice 19.03.2026 15:45
Faculty: Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD Faculty: Jennifer Sherr, MD, PhD If widespread use of continuous ketone monitoring (CKM) devices is to be safe and effective in reducing the occurrence of diabetic ketoacidosis (DKA), it is important to establish clear ketone thresholds which notify CKM users when action on their part is required. In preparation for availability and use in pra...
Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes 19.03.2026 56:45
Host: Jay B. Wish, MD Expert-curated slides on the fundamentals of cardio–kidney–metabolic (CKM) syndrome, emphasizing alignment of clinical guidelines with patient-centered care and strategies for identifying and addressing patient-level barriers to treatment.
DKA in Focus: What the New Consensus Means for Practice 19.03.2026 15:45
Faculty: Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD Faculty: Jennifer Sherr, MD, PhD If widespread use of continuous ketone monitoring (CKM) devices is to be safe and effective in reducing the occurrence of diabetic ketoacidosis (DKA), it is important to establish clear ketone thresholds which notify CKM users when action on their part is required. In preparation for availability and use in pra...
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients 13.03.2026 20:30
Faculty: David Staskin, MD Faculty: Matt T. Rosenberg, MD Faculty: Kennedy Koebbe, MSN, RN This audio-only podcast examines where contemporary approaches fall short when managing overactive bladder (OAB) in patients with complex clinical considerations, including women with persistent symptoms and men with coexisting benign prostatic hyperplasia (BPH). Faculty review clinical considerations suppor...
Applying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome 13.03.2026 16:30
Faculty: Lewis S. Blevins, Jr, MD Faculty: James W. Suliburk, MD, FACS Cushing syndrome has seen exciting advances over the last couple of years, but how do they translate into improved patient care? Let’s dig into a couple of cases and discuss!
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients 13.03.2026 20:30
Faculty: David Staskin, MD Faculty: Matt T. Rosenberg, MD Faculty: Kennedy Koebbe, MSN, RN This audio-only podcast examines where contemporary approaches fall short when managing overactive bladder (OAB) in patients with complex clinical considerations, including women with persistent symptoms and men with coexisting benign prostatic hyperplasia (BPH). Faculty review clinical considerations suppor...
Applying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome 13.03.2026 16:30
Faculty: Lewis S. Blevins, Jr, MD Faculty: James W. Suliburk, MD, FACS Cushing syndrome has seen exciting advances over the last couple of years, but how do they translate into improved patient care? Let’s dig into a couple of cases and discuss!
Ähnliche Podcasts
Höre den Podcast CME/CE in Replaio
Radio und Podcasts in einer App - kostenlos und ohne Anmeldung. Installiere sie noch heute und verpasse den Start nicht
Replaio ist kein Herausgeber von Podcasts; die Namen der Sendungen, Cover und Audioinhalte gehören ihren Autoren und werden über öffentliche RSS-Feeds verbreitet
